Program

Friday April 26th 2024

09.45-10.00h Welcome and Introduction

  • 09.45-10.00h Nuclear Medicine meets Neuro-Oncology Nathalie L. Albert (Munich), Matthias Preusser (Vienna)

10.00-12.00h Theranostic treatments: current state and future prospects

Chairs: Christophe Deroose (Leuven), Anna Berghoff (Vienna)

  • Molecular targets for theranostic treatments of CNS tumors Jolanta Kunikowska (Warsaw), 15+15´

  • Radioligand therapies for gliomas: emerging trial landscape Michael Weller (Zurich), 15+15´

  • Radioligand therapies for meningioma: emerging trial landscape Nathalie L. Albert (Munich), 15+15´

  • Theranostics for CNS metastases: overlooked potential? Matthias Preusser (Vienna), 15+15´

12.00-13.00h NMN Lunch

13.00-14.30h Proffered papers: Hot Data and Burning Questions

Chairs: Roberta Rudà (Turin), Tatjana Traub-Weidinger (Vienna)

  • Hotspot: Clinical Trials
    • Abstract 35: Role of FET-PET-based re-irradiation in recurrent glioblastoma – results of a prospective randomized clinical trial – Anca Grosu (Freiburg), 7+3´
    • Abstracts 16, 22, 23: Rhenium (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL) trial updates: ReSPECT-LM Phase 1, ReSPECT-GBM Phase 1/2, and ReSPECT-GBM Phase 2 – Andrew Brenner (San Antonio), 7+3´
    • Abstract 13: Multi-site, prospective trial evaluating FET-PET In Glioblastoma (FIG) Study (TROG 18.06): Central review of initial FET-PET biologic target volume delineation for radiation planning – Eng-Siew Koh (Sydney), 7+3´
    • Abstract 28: 11C-Methionin PET for radiotherapy treatment planning in patients with rapid early progression after glioblastoma surgery: prospective phase II trial – Tomas Kazda (Brno), 3+2´
    • Abstract 25: Feasibility and tolerability of [¹³¹I]I-PA monotherapy in progressive and recurrent high grade gliomas; a single institution case series – Nelleke Tolboom (Rotterdam), 3+2´
  • Hotspot: PET Imaging
    • Abstract 17: Assessment of FET PET-based response in patients with gliomas using the PET RANO 1.0 criteria – Norbert Galldiks (Cologne), 3+2´
    • Abstract 20: Measurable disease for response assessment in IDH-wildtype glioblastoma- a comparison of MRI-based (RANO 2.0) versus PET-based (PET RANO 1.0) assessment – Katharina Müller (Munich), 3+2´
    • Abstract 30: Prognostic value of [18F]-FET-PET in diffuse low-grade glioma (Grade 2 WHO CNS 2021) – Michael Müther (Münster), 3+2´
    • Abstract 14: Evaluation of the Utility of PET Imaging Based on WHO Classification 5th edition for Brain Tumor Diagnosis – Keisuke Miyake (Kagawa), 3+2´
    • Abstract 12: Development of [18F]AG-120 as radiotracer for the detection by positron emission tomography (PET) of the mutant isocitrate dehydrogenase 1 in glioma – Magali Toussaint (Leipzig), 3+2´
    • Abstract 40: Translating immunoPET imaging of PD-L1 in glioblastoma: journey from the laboratory to clinical practice – Gabriela Kramer-Marek (Sutton), 3+2´
  • Hotspot: Theranostics
    • Abstract 9: Promising theranostic targets for high-grade pediatric central nervous system tumors – Sabine Plasschaert (Utrecht), 3+2
    • Abstract 18: Exploring theranostic potential: FAP expression in brain metastases and novel FAPi radiotracers with an alpha-ketoamide warhead – Petr Vymola (Prague), 3+2´
    • Abstract 39: Fibroblast activating protein (FAP) expression as potential theranostics target in high-grade meningioma – Maximilian Mair (Vienna), 3+2´
    • Abstract 29: Investigating the radiobiological response to PRRT using patient-derived meningioma spheroids – Eleke Bos (Rotterdam), 3+2´

14.30-15.00h NMN Coffee

15.00-17.00h Clinical trial conduct: challenges and opportunities

Chairs: Evanthia Galanis (Rochester), Emilie Le Rhun (Zurich)

  • Investigator perspective (Clinical Neuro-Oncologist) Martin van den Bent (Rotterdam), 15+15´

  • Investigator perspective (Nuclear Medicine Physician) Wim Oyen (Milan/Arnhem), 15+15´

  • Industry perspective Daniela Niepel (Novartis) 15+15´

  • Panel discussion, 30´

17.00-18.00h Posters viewing – Drinks and Science

From 19.00h Networking Evening at the City Hall of Vienna

Saturday April 27th 2024

09.00-10.00h: Meet the Editor Session – Ulrike Harjes (Nature Medicine)

10.00-12.00h PET Imaging for Improved Patient Management

Chairs: Ingo Mellinghoff (New York), Karl Rössler (Vienna)

  • PET for neurosurgery: nice to have or must have? – Jörg-Christian Tonn (Munich), 15+15´

  • PET for radiotherapy of CNS tumors: where is the evidence? Giuseppe Minniti (Rome), 15+15´

  • PET for IDH inhibitor therapy: helpful for patient selection and monitoring? – Timothy Cloughesy (Los Angeles), 15+15´

  • What should be visualized? A clinician’s wish list – Norbert Galldiks (Cologne), 15+15´

12.00-13.00h NMN Lunch

13.00-14.30h PET Imaging: Future prospects

Chairs: Benjamin Ellingson (Los Angeles), Michael Lim (Stanford)

  • RANO 2.0 criteria for MRI-based response assessment of gliomas – Patrick Wen (Boston), 15´+15´
  • PET RANO criteria for response assessment of gliomas – Nathalie L. Albert (Munich), 15+15´
  • Do we need PET for CNS lymphomas? Marius Mayerhoefer (New York), 15+15´

14.30-15.00h NMN Coffee

15.00-17.00h Radiopharmacology: understanding the basics

Chairs: Erik Sulman (New York), Marcus Hacker (Vienna)

  • Tracer development for theranostics: how to construct a magic bullet Clemens Kratochwil (Heidelberg) , 15+15´

  • Optimizing radioligand therapy delivery to CNS tumors: role of the blood-brain/blood tumor barrier Nelleke Tolboom (Utrecht), 15+15´

  • Do we need dosimetry for optimization of theranostics in CNS tumors? Francesco Cicone (Catanzaro), 15+15´

  • Panel discussion, 30´

17.00h Conclusion and Farewell

Note that the programme is subject to change and will be continuously updated.

All times refer to Central European Summer Time (CEST).

To download the program, click here: